Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin · Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MouseChemical/toxinC57BL/6MaleOral administration10 mg/kg or 30 mg/kgStarted one week before doxorubicin injection and continued afterwards
Model: Doxorubicin-induced acute cardiac injury, doxorubicin 15 mg/kg in 200 microlitres phosphate-buffered saline intraperitoneally
Asiatic acid attenuated cardiac injury and improved cardiac function after doxorubicin, suppressed myocardial oxidative damage and apoptosis in a dose-dependent manner without affecting cardiac inflammation, and improved cardiomyocyte viability in vitro; protection was lost with AKT inactivation, a…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
RatSpinal cord injuryUnspecifiedSprague-Dawleyn = 150 rats randomly assigned to five groups30 mg/kg and 75 mg/kg
Model: Spinal cord injury-induced acute lung injury
Asiatic acid at 30 and 75 mg/kg reduced lung wet-to-dry ratio, pulmonary permeability index and histological injury, lowered neutrophil infiltration, myeloperoxidase, cytokines, reactive oxygen species and malondialdehyde, raised superoxide dismutase and catalase, upregulated Nrf2 and downregulated…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
